R-Pharm JSC
http://r-pharm.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From R-Pharm JSC
Asia Deal Watch: Bone Therapeutics Licenses Bone Cell Therapy Tech To Two Asian Firms
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.
Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea
Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.
Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
TRPharm Chair: 'Dr Reddy's Partnership Is Key To International Expansion'
Turkey's TRPharm, in partnership with India's Dr Reddy's, has become the first company to gain a license for an oncology biosimilar Mab product in Turkey. Chairman Mehmet Göker spoke to Scrip about the company's international expansion plans.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
- Diagnostic Imaging Equipment & Supplies
- Monitoring Equipment & Devices
-
Diagnostic Imaging Equipment & Supplies
- Ultrasound
- Other Names / Subsidiaries
-
- TR-Pharm (Turkey)
- R-PHARM US